1025424-06-9

Basic information

• Product Name: 5-methoxy-2-[(4-methylphenyl)sulfonyl]isoindoline
• Synonyms: 5-methoxy-2-[(4-methylphenyl)sulfonyl]isoindoline
• CAS NO: 1025424-06-9
• Molecular Weight: 303.382
• Mol File: 1025424-06-9.mol

Chemical Properties

• CAS DataBase Reference: 5-methoxy-2-[(4-methylphenyl)sulfonyl]isoindoline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methoxy-2-[(4-methylphenyl)sulfonyl]isoindoline(1025424-06-9)
• EPA Substance Registry System: 5-methoxy-2-[(4-methylphenyl)sulfonyl]isoindoline(1025424-06-9)

Safety Data

• Hazardous Substances Data: 1025424-06-9(Hazardous Substances Data)

Upstream product

• 36132-96-4 1,2-bis(bromomethyl)-4-methoxybenzene 
• 18522-92-4 sodium p-toluenesulfonamide 
• 70-55-3 toluene-4-sulfonamide 

Downstream Products

• 127168-88-1 5-methoxy-2,3-dihydro-1H-isoindole 

Relevant articles and documents

SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5-tetrahydro-1H-2-benzazepine and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.

Bronchorelaxing agents based on indol- and isoquinoline derivatives

A compound of formula (I) and its acid addition salts, wherein R1-FIj are H, lower (CrC6) alkyl; halogen; NR5R6, wherein R5, R6 are H, lower alkyl, C2-C6 acyl, SO2R7, wherein R7 is lower alkyl, CF3, aryl, substituted aryl; CN; COR8, wherein R8 is H, OH, lower alkyl, lower alkoxy; SO2R9, wherein R9 is OR10, wherein R10 is H, lower alkyl or NRnR12, wherein R11 and R12 is H or lower alkyl; ORi3, wherein R13 is H, lower alkyl, C2-C6 acyl, C1-C8 carboxy, C1-C8 carbamoyl; X is O or S; A is H, lower alkyl; B is C1-C18 alkyl optionally substituted; M is zero or 1; with the proviso that no more than three of R1-R4 are H, for treating and preventing bronchoconstructive pulmonary disease.

COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV

The invention aims to provide a dipeptidyl peptidase IV inhibitor which is satisfactory in respect of activity, stability and safety and has an excellent action as a pharmaceutical agent. The invention is directed to a compound represented by the following general formula or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each represents hydrogen, an optionally substituted C1-6 alkyl group, or -COOR5 whereupon R5 represents hydrogen or an optionally substituted C1-6 alkyl group, or R1 and R2, together with a carbon atom to which they are bound, represent a 3- to 6-membered cycloalkyl group, R3 represents hydrogen or an optionally substituted C6-10 aryl group, R4 represents a hydrogen or a cyano group, D represents -CONR6-, -CO- or -NR6CO-, R6 represents hydrogen or an optionally substituted C1-6 alkyl group, E represents -(CH2)m- whereupon m is an integer of 1 to 3, -CH2OCH2-, or -SCH2-, n is an integer of 0 to 3, and A represents an optionally substituted bicyclic heterocyclic group or bicyclic hydrocarbon group.